WHAT IS NEOVAULT®?
NEOVAULT®:
The Next Generation Digital Drug & Impairment Testing Solution
NEOVAULT® is an AI-enhanced reader that accurately reads, records, and reports point-of-care (POC) drug and alcohol test results. As the companion database, NEOVAULT® securely stores and manages test data, ensuring seamless digital reporting and enhanced decision-making.
Developed by Neopharma Technologies, our cutting-edge AI VISION technology operates through a mobile app, streamlining the testing process while reducing human error and ensuring test integrity.
NEOVAULT® is an AI-powered solution that captures and processes point-of-care (POC) drug and alcohol test results from both curved and flat surfaces with precision. The AI VISION reader securely stores results offline and automatically transmits them to NEOVAULT® once a network connection is available.
Designed for flexibility, NEOVAULT® can deliver test results via email or function as a comprehensive ERM system, offering customizable reporting and seamless API integration with third-party platforms. Certified to ISO 27001, HIPAA, GDPR, and SOC 2 Type 2 standards, it ensures top-tier data security and regulatory compliance.
This is why NEOVAULT® is the future of digital drug and impairment testing!
Software Workflow
Cloud Based Software
The NEOVAULT® platform offers flexible configurations to meet your company needs. With advanced reporting capabilities based on customizable parameters and seamless API integration with third-party software, NEOVAULT® is designed to adapt to your specific requirements.
Mobile App
The NEOVAULT® app streamlines donor verification and test documentation through our integrated chain of custody workflow. Our advanced AI technology accurately reads results for collector verification -- delivering test reports in seconds via our secure platform. Experience fast, reliable, and secure reporting like never before.
ENABLED Test Kit
NEOVAULT®’s digital platform integrates with any drug or alcohol testing device. Whether purchased separately or directly from Neopharma Technologies, results are delivered in minutes.
Impairment Testing
Neopharma Technologies is proud to partner with Impairment Science, Inc. in launching a groundbreaking innovation: the world’s first integration of rapid drug testing with cognitive impairment technology. This cutting-edge solution meets the rising demand for efficient, objective impairment measurement in workplaces and on the roadside, setting a new standard for safety and accuracy.
Dual Advantage
Designed specifically for the challenges of cannabis legalization, this cutting-edge technology combination offers employers a powerful dual advantage: it not only tests for the presence of drugs, including THC, but also delivers a rapid, accurate, and objective assessment of cognitive impairment. This solution helps employers navigate the complexities of THC testing with confidence and precision.
Improves Staff Retention
Provides THC Solution
Streamlines the hiring process
Reduces costs
Emerging Trends
As the shift moves from pre-employment drug testing to continuous workplace monitoring, Neopharma Technologies and Impairment Science offer the market’s only solution with dual capabilities – rapid drug testing and impairment. Testing is conducted through a user-friendly app, requiring no additional equipment for measuring and recording results. This seamless integration provides employers with a reliable, efficient method to determine if there is cognitive impairment that indicates recent use of THC on the job, immediately before work or during a break.
No additional equipment required
Enhanced accuracy and efficiency
Ensures a safe and productive work environment
Neopharma Technologies Ltd is excited to partner with Impairment Science Inc. to introduce the world's first integration of rapid drug testing with cognitive impairment technology. Contact us today to learn how our “NEO Next Generation” technologies can enhance safety, efficiency, and compliance within your organization or business.